p); ivacaftor is a weak inhibitor of P-gp. Ivacaftor is also a weak inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Magnesium Hydroxide: Separate the use of antacids and velpatasvir administration by 4 hours. Velpatasvir solubility decreases as pH increases; therefore, drugs that increase gastric pH are expected to decrease the concentrations of velpatasvir, potentially resulting in loss of antiviral efficacy.
Mefloquine: Use caution when administering velpatasvir with mefloquine. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp).
Metformin; Pioglitazone: Use caution when administering velpatasvir with pioglitazone. Taking these drugs together may decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; pioglitazone is a weak inducer of CYP3A4.
Metyrapone: Avoid coadministration of velpatasvir with metyrapone. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; metyrapone is an inducer of CYP3A4.
Mifepristone, RU-486: Use caution when administering velpatasvir with mifepristone, RU-486. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); mifepristone is an inhibitor of P-gp. Mifepristone is also an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Mirabegron: Use caution when administering velpatasvir with mirabegron. Taking these medications together may increase the plasma concentrations of velpatasvir and mirabegron, potentially resulting in adverse events. Mirabegron is a substrate for the drug transporters P-glycoprotein (P-gp). Velpatasvir is an inhibitor of P-gp. Mirabegron is also a mild CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Mitotane: Avoid coadministration of velpatasvir with mitotane. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; mitotane is a potent inducer of CYP3A4.
Modafinil: Avoid coadministration of velpatasvir with inducers of CYP3A4 and CYP2B6, such as modafinil. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 and CYP2B6 substrate.
Nafcillin: Avoid coadministration of velpatasvir with nafcillin. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; nafcillin is an in vitro inducer of CYP3A4.
Nefazodone: Use caution when administering velpatasvir with nefazodone. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Nefazodone is a potent CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Nelfinavir: Use caution when administering velpatasvir with nelfinavir. Taking these medications together may increase the plasma concentrations of both dru |
